Cullinan Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.1M | Buy |
51,762
+450
| +0.9% | +$210K | 1.87% | 13 |
|
|
2025
Q4 | $23.3M | Sell |
51,312
-100
| -0.2% | -$43.1K | 1.58% | 14 |
|
|
2025
Q3 | $20.1M | Sell |
51,412
-600
| -1% | -$251K | 1.31% | 19 |
|
|
2025
Q2 | $23.2M | Sell |
52,012
-1,100
| -2% | -$507K | 1.53% | 16 |
|
|
2025
Q1 | $25.7M | Sell |
53,112
-50
| -0.1% | -$23.3K | 1.82% | 12 |
|
|
2024
Q4 | $21.4M | Sell |
53,162
-1,500
| -3% | -$695K | 1.37% | 16 |
|
|
2024
Q3 | $26.2M | Sell |
54,662
-1,000
| -2% | -$480K | 1.48% | 15 |
|
|
2024
Q2 | $26.1M | Sell |
55,662
-614
| -1% | -$267K | 1.48% | 14 |
|
|
2024
Q1 | $23.5M | Sell |
56,276
-2,000
| -3% | -$845K | 1.32% | 18 |
|
|
2023
Q4 | $23.7M | Sell |
58,276
-2,800
| -5% | -$1.03M | 1.32% | 15 |
|
|
2023
Q3 | $21.2M | Sell |
61,076
-900
| -1% | -$315K | 1.24% | 19 |
|
|
2023
Q2 | $21.8M | Sell |
61,976
-2,600
| -4% | -$876K | 1.2% | 16 |
|
|
2023
Q1 | $20.3M | Sell |
64,576
-305
| -0.5% | -$91.5K | 1.19% | 20 |
|
|
2022
Q4 | $18.7M | Sell |
64,881
-19,400
| -23% | -$5.91M | 1.04% | 17 |
|
|
2022
Q3 | $24.4M | Sell |
84,281
-4,650
| -5% | -$1.34M | 1.54% | 10 |
|
|
2022
Q2 | $25.1M | Sell |
88,931
-9,385
| -10% | -$2.51M | 1.53% | 10 |
|
|
2022
Q1 | $25.7M | Sell |
98,316
-594
| -0.6% | -$141K | 1.35% | 10 |
|
|
2021
Q4 | $21.7M | Sell |
98,910
-215
| -0.2% | -$41.8K | 1.11% | 15 |
|
|
2021
Q3 | $18M | Sell |
99,125
-2,610
| -3% | -$510K | 0.99% | 23 |
|
|
2021
Q2 | $20.5M | Sell |
101,735
-2,700
| -3% | -$565K | 1.15% | 14 |
|
|
2021
Q1 | $22.4M | Buy |
104,435
+10,800
| +12% | +$2.37M | 1.29% | 10 |
|
|
2020
Q4 | $22.1M | Buy |
93,635
+4,925
| +6% | +$1.13M | 1.33% | 9 |
|
|
2020
Q3 | $24.1M | Sell |
88,710
-5,679
| -6% | -$1.57M | 1.56% | 8 |
|
|
2020
Q2 | $27.4M | Buy |
94,389
+1,477
| +2% | +$400K | 1.92% | 7 |
|
|
2020
Q1 | $22.1M | Buy |
92,912
+1,641
| +2% | +$376K | 1.81% | 7 |
|
|
2019
Q4 | $20M | Sell |
91,271
-10,824
| -11% | -$2.19M | 1.34% | 13 |
|
|
2019
Q3 | $17.3M | Hold |
102,095
| – | – | 1.23% | 12 |
|
|
2019
Q2 | $18.7M | Sell |
102,095
-8,378
| -8% | -$1.46M | 1.36% | 9 |
|
|
2019
Q1 | $20.3M | Sell |
110,473
-6,800
| -6% | -$1.26M | 1.53% | 7 |
|
|
2018
Q4 | $19.4M | Buy |
117,273
+5,472
| +5% | +$948K | 1.6% | 8 |
|
|
2018
Q3 | $21.5M | Sell |
111,801
-8,541
| -7% | -$1.52M | 1.56% | 7 |
|
|
2018
Q2 | $20.5M | Buy |
120,342
+21,795
| +22% | +$3.38M | 1.56% | 8 |
|
|
2018
Q1 | $16.1M | Buy |
98,547
+600
| +0.6% | +$98K | 1.22% | 11 |
|
|
2017
Q4 | $14.7M | Buy |
97,947
+1,093
| +1% | +$162K | 1.08% | 16 |
|
|
2017
Q3 | $14.7M | Sell |
96,854
-12,014
| -11% | -$1.81M | 1.13% | 15 |
|
|
2017
Q2 | $14M | Buy |
108,868
+21,743
| +25% | +$2.62M | 1.09% | 16 |
|
|
2017
Q1 | $9.53M | Sell |
87,125
-38,085
| -30% | -$3.35M | 0.78% | 33 |
|
|
2016
Q4 | $9.22M | Sell |
125,210
-2,800
| -2% | -$228K | 0.79% | 31 |
|
|
2016
Q3 | $11.2M | Hold |
128,010
| – | – | 0.95% | 19 |
|
|
2016
Q2 | $11M | Buy |
128,010
+27,323
| +27% | +$2.36M | 0.9% | 20 |
|
|
2016
Q1 | $8M | Hold |
100,687
| – | – | 0.68% | 37 |
|
|
2015
Q4 | $12.7M | Hold |
100,687
| – | – | 1.1% | 17 |
|
|
2015
Q3 | $10.5M | Hold |
100,687
| – | – | 0.96% | 18 |
|
|
2015
Q2 | $12.4M | Hold |
100,687
| – | – | 1.03% | 15 |
|
|
2015
Q1 | $11.9M | Buy |
+100,687
| New | +$12.1M | 0.92% | 16 |
|
Other funds holding VRTX
VCM
VPM
Cullinan Associates's VRTX Position: Q1 2026 in Review
Cullinan Associates increased its Vertex Pharmaceuticals (VRTX) stake by 0.88% in Q1 2026, buying an estimated $210K and bringing the position to 51,762 shares worth $23.1M. The position accounts for 1.87% of the portfolio, ranked #13.
Cullinan Associates first reported a position in VRTX in Q1 2015 and has held it in 45 quarters since. The position peaked at $27.4M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Cullinan Associates held 51,762 shares of Vertex Pharmaceuticals worth $23.1M as of Q1 2026.
- Cullinan Associates bought 450 Vertex Pharmaceuticals shares in Q1 2026, an estimated $210K.
- Vertex Pharmaceuticals made up 1.87% of Cullinan Associates's portfolio in Q1 2026, its #13 holding.
- Cullinan Associates first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- Cullinan Associates's Vertex Pharmaceuticals position peaked at $27.4M in Q2 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.